Association Between Vitamin D and Statin-Related Myopathy: A Meta-analysis
Am J Cardiovasc Drugs. 2021 Jul 23. doi: 10.1007/s40256-021-00492-8 PDF costs $50
Qingtao Hou 1, Caishuang Pang 2, Yuqin Chen 3
Statins and Vitamin D - many studies >25 major entries as of July 2021
If you really must take statins and they cause pain, vitamin D will relieve the pain - 2015
Apparently: Stains ==> less cholesterol ==> less pre-vitamin D ==> less vitamin D from sun
VitaminDWiki pages containing "STATIN" in title
Background: Myopathy is the most widely reported statin-associated adverse event. Several studies have linked vitamin D deficiency with statin-related myopathy.
Objective: This meta-analysis aimed to investigate whether adult patients with statin-related myopathy have a lower 25-hydroxyvitamin D (25OHD) level than patients without myopathy and whether statin-related myopathy in vitamin D-deficient patients can be improved by vitamin D supplementation.
Methods: PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials were searched until 28 September 2020. Original studies comparing the 25OHD levels of patients with and without myopathy or detecting the impact of vitamin D supplementation on statin-related muscular intolerance were included. Subgroup analyses based on the sample size and baseline 25OHD level were conducted.
Results: This meta-analysis, based on nine cohort studies with a total of 2906 patients, revealed that the 25OHD level of patients with statin-related myopathy was significantly lower than that of patients without myopathy [weighted mean difference - 4.17 ng/mL; 95% confidence interval (CI) - 7.70 to - 0.63; p = 0.021]. The overall analysis from another four studies with 446 patients who were previously vitamin D deficient and reported statin-related muscular intolerance showed that the pooled tolerance rate of statins improved to 89% (95% CI 8692; p < 0.001) after vitamin D supplementation.
Conclusions: The present meta-analysis provides evidence that low 25OHD level is associated with statin-related myopathy and that exogenous vitamin D supplementation can improve statin-related muscular intolerance associated with low 25OHD level in most cases. Our findings may provide useful insight for the prevention and treatment of statin-related myopathy.
- Taylor BA, Thompson PD. Statin-associated muscle disease: advances in diagnosis and management. Neurotherapeutics. 2018;15(4):1006–17. - DOI
- Newman CB, Preiss D, Tobert JA, Jacobson TA, Page RL 2nd, Goldstein LB, et al. Statin safety and associated adverse events: a scientific statement from the American heart association. Arterioscler Thromb Vasc Biol. 2019;39(2):e38–81. - DOI
- Thompson PD, Panza G, Zaleski A, Taylor B. Statin-associated side effects. J Am Coll Cardiol. 2016;67(20):2395–410. - DOI
- Cohen JD, Brinton EA, Ito MK, Jacobson TA. Understanding statin use in america and gaps in patient education (USAGE): an internet-based survey of 10,138 current and former statin users. J Clin Lipidol. 2012;6(3):208–15. - DOI
- Sewright KA, Clarkson PM, Thompson PD. Statin myopathy: incidence, risk factors, and pathophysiology. Curr Atheroscler Rep. 2007;9(5):389–96. - DOI
- Domingues-Faria C, Boirie Y, Walrand S. Vitamin D and muscle trophicity. Curr Opin Clin Nutr Metab Care. 2017;20(3):169–74. - DOI
- Gupta A, Thompson PD. The relationship of vitamin D deficiency to statin myopathy. Atherosclerosis. 2011;215(1):23–9. - DOI
- Ovesjö ML, Skilving I, Bergman P, Rane A, Ekström L, Björkhem-Bergman L. Low vitamin D levels and genetic polymorphism in the vitamin D receptor are associated with increased risk of statin-induced myopathy. Basic Clin Pharmacol Toxicol. 2016;118(3):214–8. - DOI
- Riche KD, Arnall J, Rieser K, East HE, Riche DM. Impact of vitamin D status on statin-induced myopathy. J Clin Transl Endocrinol. 2016;6:56–9. - PubMed - PMC
- Wells G, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2013. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp . Accessed 1 Jun 2011
- Zeng X, Zhang Y, Kwong JS, Zhang C, Li S, Sun F, et al. The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review. J Evid Based Med. 2015;8(1):2–10. - DOI
- Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–58. - DOI
- Hayashino Y, Noguchi Y, Fukui T. Systematic evaluation and comparison of statistical tests for publication bias. J Epidemiol. 2005;15(6):235–43. - DOI
- LeBlanc ES, Zakher B, Daeges M, Pappas M, Chou R. Screening for vitamin D deficiency: a systematic review for the U.S. preventive services task force. Ann Intern Med. 2015;162(2):109–22. - DOI
- Ahmed W, Khan N, Glueck CJ, Pandey S, Wang P, Goldenberg N, et al. Low serum 25 (OH) vitamin D levels (< 32 ng/mL) are associated with reversible myositis-myalgia in statin-treated patients. Transl Res. 2009;153(1):11–6. - DOI
- Minissian M, Agarwal M, Shufelt C, Mehta PK, Waldman T, Lentz G, et al. Do women with statin-related myalgias have low vitamin D levels? BMC Res Notes. 2015;8:449. - DOI
- Pennisi M, Bartolo GD, Malaguarnera G, Bella R, Lanza G, Malaguarnera M. Vitamin D serum levels in patients with statin-induced musculoskeletal pain. Dis Mark. 2019;2019:3549402. https://doi.org/10.1155/2019/3549402 . eCollection 2019.
- Taşoğlu Ö, Kutsal YG, Taşoğlu İ, Özdemİr O, Erdoğanoğlu Y. Is Vitamin D deficiency a risk factor for the development of statin-induced myalgia in patients receiving statins? Turkiye Fiziksel Tip ve Rehabilitasyon Dergisi. 2015;61(4):314–9. - DOI
- Backes JM, Barnes BJ, Ruisinger JF, Moriarty PM. A comparison of 25-hydroxyvitamin D serum levels among those with or without statin-associated myalgias. Atherosclerosis. 2011;218(1):247–9. - DOI
- Calza L, Magistrelli E, Colangeli V, Borderi M, Contadini I, Bon I, et al. Significant association between statin-associated myalgia and vitamin D deficiency among treated HIV-infected patients. AIDS. 2017;31(5):681–8. - DOI
- Linde R, Peng L, Desai M, Feldman D. The role of vitamin D and SLCO1B1*5 gene polymorphism in statin-associated myalgias. Dermatoendocrinology. 2010;2(2):77–84. - DOI
- Ovesjö ML, Skilving I, Bergman P, Rane A, Ekström L, Björkhem-Bergman L. Low vitamin D levels and genetic polymorphism in the vitamin D receptor are associated with increased risk of statin-induced myopathy. Basic Clin Pharmacol Toxicol. 2015;118(3):214–8. - DOI
- Palamaner SG, Ramos J, Thomas-Hemak L, Pancholy SB. Association of vitamin D and incident statin induced myalgia—a retrospective cohort study. PLoS ONE. 2014;9(2):e88877. - DOI
- Riphagen IJ, van der Veer E, Muskiet FA, DeJongste MJ. Myopathy during statin therapy in the daily practice of an outpatient cardiology clinic: prevalence, predictors and relation with vitamin D. Curr Med Res Opin. 2012;28(7):1247–52. - DOI
- Mergenhagen K, Ott M, Heckman K, Rubin LM, Kellick K. Low vitamin D as a risk factor for the development of myalgia in patients taking high-dose simvastatin: a retrospective review. Clin Ther. 2014;36(5):770–7. - DOI
- Eisen A, Lev E, Iakobishvilli Z, Porter A, Brosh D, Hasdai D, et al. Low plasma vitamin D levels and muscle-related adverse effects in statin users. Isr Med Assoc J. 2014;16(1):42–5. - PubMed
- Glueck CJ, Abuchaibe C, Wang P. Symptomatic myositis-myalgia in hypercholesterolemic statin-treated patients with concurrent vitamin D deficiency leading to statin intolerance may reflect a reversible interaction between vitamin D deficiency and statins on skeletal muscle. Med Hypotheses. 2011;77(4):658–61. - DOI
- Glueck CJ, Budhani SB, Masineni SS, Abuchaibe C, Khan N, Wang P, et al. Vitamin D deficiency, myositis-myalgia, and reversible statin intolerance. Curr Med Res Opin. 2011;27(9):1683–90. - DOI
- Khayznikov M, Hemachrandra K, Pandit R, Kumar A, Wang P, Glueck CJ. Statin intolerance because of myalgia, myositis, myopathy, or myonecrosis can in most cases be safely resolved by vitamin D supplementation. N Am J Med Sci. 2015;7(3):86–93. - DOI
- Jetty V, Glueck CJ, Wang P, Shah P, Prince M, Lee K, et al. Safety of 50,000–100,000 units of vitamin D3/week in vitamin D-deficient, hypercholesterolemic patients with reversible statin intolerance. N Am J Med Sci. 2016;8(3):156–62. - DOI
- Bhattacharyya S, Bhattacharyya K, Maitra A. Possible mechanisms of interaction between statins and vitamin D. QJM. 2012;105(5):487–91. - DOI
- Carlberg C. Nutrigenomics of Vitamin D. Nutrients. 2019;11(3): 676. https://doi.org/10.3390/nu11030676 .
- Dirks AJ, Jones KM. Statin-induced apoptosis and skeletal myopathy. Am J Physiol Cell Physiol. 2006;291(6):C1208–12. - DOI
- Michalska-Kasiczak M, Sahebkar A, Mikhailidis DP, Rysz J, Muntner P, Toth PP, et al. Analysis of vitamin D levels in patients with and without statin-associated myalgia—a systematic review and meta-analysis of 7 studies with 2420 patients. Int J Cardiol. 2015;178:111–6. - DOI
- Pereda CA, Nishishinya MB. Is there really a relationship between serum vitamin D (25OHD) levels and the musculoskeletal pain associated with statin intake? A systematic review. Reumatol Clín (Engl Ed). 2016;12(6):331–5. - DOI
- Bell DS. Resolution of statin-induced myalgias by correcting vitamin D deficiency. South Med J. 2010;103(7):690–2. - DOI
- Gerrard G. Fatal statin-induced rhabdomyolysis in the Australian indigenous population and vitamin D replacement—new concepts. Endocr Rev 2011;32(3). https://www.embase.com/search/results?subaction=viewrecord&id=L70676666&...
- Rosenson RS, Baker SK, Jacobson TA, Kopecky SL, Parker BA. The National Lipid Association’s Muscle Safety Expert P. An assessment by the Statin Muscle Safety Task Force: 2014 update. J Clin Lipidol. 2014;8(3 Suppl):58–71. - DOI
- Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S1-45. - PubMed
- Stulc T, Ceška R, Gotto AM Jr. Statin intolerance: the clinician’s perspective. Curr Atheroscler Rep. 2015;17(12):69. - DOI
- Camerino GM, De Bellis M, Conte E, Liantonio A, Musaraj K, Cannone M, et al. Statin-induced myotoxicity is exacerbated by aging: A biophysical and molecular biology study in rats treated with atorvastatin. Toxicol Appl Pharmacol. 2016;306:36–46. - DOI